Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Notes Payables (2020 - 2025)

Catheter Precision (VTAK) has disclosed Notes Payables for 5 consecutive years, with $1.7 million as the latest value for Q2 2025.

  • On a quarterly basis, Notes Payables changed N/A to $1.7 million in Q2 2025 year-over-year; TTM through Jun 2025 was $1.7 million, a N/A change, with the full-year FY2024 number at $177000.0, down 3.8% from a year prior.
  • Notes Payables was $1.7 million for Q2 2025 at Catheter Precision, up from $1.6 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $14.2 million in Q2 2023 to a low of $7592.0 in Q1 2023.
  • A 4-year average of $3.7 million and a median of $674000.0 in 2021 define the central range for Notes Payables.
  • Biggest YoY gain for Notes Payables was 3.8% in 2024; the steepest drop was 98.24% in 2024.
  • Catheter Precision's Notes Payables stood at $674000.0 in 2021, then plummeted by 72.7% to $184000.0 in 2023, then fell by 3.8% to $177000.0 in 2024, then skyrocketed by 860.45% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Notes Payables are $1.7 million (Q2 2025), $1.6 million (Q1 2025), and $177000.0 (Q4 2024).